Company Filing History:
Years Active: 2015-2020
Title: Frances Rosemary Balkwill: Innovator in Cancer Research
Introduction
Frances Rosemary Balkwill is a prominent inventor based in London, GB. She has made significant contributions to the field of cancer research, particularly through her innovative patents. With a total of 4 patents, her work focuses on the development of therapeutic targets and diagnostic markers for cancer treatment.
Latest Patents
Among her latest patents is the invention of anti-CXCL12 antibody molecules and their uses. These molecules are designed to inhibit the biological activity of CXCL12 both in vitro and in vivo, providing potential treatments for CXCL12-mediated diseases. Another notable patent involves the identification of chemokine receptor CCR4 and its ligands CCL17 and CCL22 as markers for cancer. This invention highlights the increasing levels of these markers during malignant tumor progression, offering methods for stratifying cancer patients based on their suitability for anti-cancer treatments.
Career Highlights
Frances Balkwill is associated with Cancer Research Technology Limited, where she continues to advance her research and innovations. Her work has been instrumental in developing methods of treatment for cancer patients, utilizing agents that modulate the activity of CCR4, CCL17, and CCL22.
Collaborations
Frances has collaborated with notable colleagues, including Violet Slettenaar and Julia Wilson, contributing to a dynamic research environment focused on cancer therapies.
Conclusion
Frances Rosemary Balkwill's contributions to cancer research through her patents and collaborations underscore her role as a leading innovator in the field. Her work continues to pave the way for advancements in cancer treatment and diagnostics.